(UroToday.com) The KEYNOTE-052 trial showed that pembrolizumab monotherapy has durable antitumor activity as first-line therapy in cisplatin-ineligible patients with locally advanced unresectable or metastatic urothelial carcinoma (UC)1. Moreover, pembrolizumab has also shown durable activity as 2nd line therapy in patients with platinum-refractory advanced UC in the KEYNOTE-045 trial2.